BGM

BGM Group Ltd.

$8.01

-2.91%

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions.

Source: Yahoo Finance
Q-Score37/ 100
Market Cap$107M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta0.65
AI summary

Price & performance

1M+19.1%
3M+6.0%
YTD-91.6%
1Y-96.7%
52-week range—
Beta0.65
Full chart and returns against a benchmark

Q-Score

37/ 100

Quality against peers; 50 is the peer median.

Growth36
Risk34
Performance33
Valuation63
Profitability41
Leverage45
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$37.9M+51.1%
Net income-$19.9M
Net margin-52.6%-46.8 pts
Historical fundamentals

Red flags in filings

2active red flags
Material weakness in controlsJul 21, 2026
Late filing noticeJan 30, 2026
Filings, findings and the timeline

Revenue exposure

Largest customer17%
Regions, segments, customers and suppliers

Valuation

BGMIndustryP/E—35.25P/S2.822.74EV/EBITDA—16.35P/B0.272.46PEG—0.87
Dividend yield0.00%
Every valuation metric